2021-11-10| Special

Experts Weigh on How COVID Vaccine Development Has Prepared Us for the Next Pandemic

by Sahana Shankar
Share To
The COVID-19 pandemic was a major disruptive force to propel major innovation, scale, and capacity building in vaccine development. The last two years have seen an unprecedented acceleration in vaccine research, regulatory approvals, and consumer readiness. In a panel discussion titled “Future of Vaccines’,  at the Financial Times Global Pharmaceutical and Biotechnology Conference, industry experts shared their lessons from the COVID-19 pandemic.

The panel, moderated by Greg Reh, Global Life Sciences and Healthcare Industry leader, Deloitte, comprised of

Judy Stewart, Senior Vice President, Head of US vaccines, GlaxoSmithKline Lovisa Afzelius, Origination Partner, Flagship Pioneering Nell Beattie, Chief Business Officer, VBI Vaccines Rasmus Bech Hansen, Co-Founder, and CEO, Airfinity

Log in now to read

Biotech Showcase 2022: Healing the Psyche with Psychedelia
Sex Dimorphism in Obesity and the Impact of Estrogen Hormone Therapy on Cardiometabolic Health
ARM 2022: Industry Briefs on Cell and Gene Therapies
Study Reveals a Form of Four-Stranded DNA that Links Protein Deficiency and Premature Aging
Shanghai’s Everest Medicines Licenses Covid-19 Oral Antivirals from Singapore’s National Drug Discovery Platform
Digital Health Programme to Connect British and Taiwanese Leaders
Pfizer: Pneumonia Shot Can Be Given with COVID-19 Vaccine in Older Adults
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!